|
1
|
Hull RD, Garcia DA and Vazquez SR:
Warfarin and other VKAs: Dosing and adverse effects. UpToDate,
Waltham, MA. 2019.https://www.uptodate.com/contents/warfarin-and-other-vkas-dosing-and-adverse-effects.
Accessed May 29, 2019.
|
|
2
|
Mekaj YH, Mekaj AY, Duci SB and Miftari
EI: New oral anticoagulants: Their advantages and disadvantages
compared with vitamin K antagonists in the prevention and treatment
of patients with thromboembolic events. Ther Clin Risk Manag.
11:967–977. 2015.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Abed HS, Kilborn MJ, Chen V and Sy RW:
Reversal agents in the era of NOACs. J Atr Fibrillation.
10(1634)2017.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Petca A, Petca RC, Zvanca M, Maru N,
Mastalier B and Dogaroiu C: Fetal death from ruptured vasa previa:
A tragic event in the ultrasonographic era. Rev Med Leg. 27:43–46.
2019. View Article : Google Scholar
|
|
5
|
Petca AT, Vlădăreanu S, Radu DC, BoŢ M,
Berceanu C, Mastalier Manolescu BS, Medar C and Petca RC:
Morphological, imaging and surgical aspects in a complex case of
uterine leiomyosarcoma - case report and review of the literature.
Rom J Morphol Embryol. 58:619–625. 2017.PubMed/NCBI
|
|
6
|
Weitz JI: Expanding use of new oral
anticoagulants. F1000Prime Rep. 6(93)2014.PubMed/NCBI View
Article : Google Scholar
|
|
7
|
European Medicines Agency: Xarelto.
European Medicines Agency, 2019. https://www.ema.europa.eu/en/medicines/human/EPAR/xarelto#authorisation-details-section.
Accessed May 29, 2019.
|
|
8
|
European Medicines Agency: Eliquis.
European Medicines Agency, 2019. https://www.ema.europa.eu/en/medicines/human/EPAR/eliquis.
Accessed May 29, 2019.
|
|
9
|
European Medicines Agency: Lixiana.
European Medicines Agency, 2019. https://www.ema.europa.eu/en/medicines/human/EPAR/lixiana.
Accessed May 29, 2019.
|
|
10
|
European Medicines Agency: Pradaxa.
European Medicines Agency, 2019. https://www.ema.europa.eu/en/medicines/human/EPAR/pradaxa.
Accessed May 29, 2019.
|
|
11
|
Burke A: Pathology of Acute Myocardial
Infarction. Medscape. 2015.https://emedicine.medscape.com/article/1960472-overview.
Accessed October 26, 2015.
|
|
12
|
Montalescot G, Sechtem U, Achenbach S,
Andreotti F, Arden C, Budaj A, Bugiardini R, Crea F, Cuisset T, Di
Mario C, et al: Document Reviewers: 2013 ESC guidelines on the
management of stable coronary artery disease: The Task Force on the
management of stable coronary artery disease of the European
Society of Cardiology. Eur Heart J. 34:2949–3003. 2013.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Aboyans V, Ricco JB, Bartelink MEL, Björck
M, Brodmann M, Cohnert T, Collet JP, Czerny M, De Carlo M, Debus S,
et al: ESC Scientific Document Group. 2017 ESC Guidelines on the
Diagnosis and Treatment of Peripheral Arterial Diseases, in
collaboration with the European Society for Vascular Surgery
(ESVS): Document covering atherosclerotic disease of extracranial
carotid and vertebral, mesenteric, renal, upper and lower extremity
arteries. Endorsed by: the European Stroke Organization (ESO)The
Task Force for the Diagnosis and Treatment of Peripheral Arterial
Diseases of the European Society of Cardiology (ESC) and of the
European Society for Vascular Surgery (ESVS). Eur Heart J.
39:763–816. 2018.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Bhatt DL, Fox KA, Hacke W, Berger PB,
Black HR, Boden WE, Cacoub P, Cohen EA, Creager MA, Easton JD, et
al: CHARISMA Investigators: Clopidogrel and aspirin versus aspirin
alone for the prevention of atherothrombotic events. N Engl J Med.
354:1706–1717. 2006. View Article : Google Scholar
|
|
15
|
Warfarin Antiplatelet Vascular Evaluation
Trial Investigators, Anand S, Yusuf S, et al: Oral anticoagulant
and antiplatelet therapy and peripheral arterial disease. N Engl J
Med. 357:217–227. 2007.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Knuuti J, Wijns W, Saraste A, Capodanno D,
Barbato E, Funck-Brentano C, Prescott E, Storey RF, Deaton C,
Cuisset T, et al: 2019 ESC Guidelines for the diagnosis and
management of chronic coronary syndromes: The Task Force for the
diagnosis and management of chronic coronary syndromes of the
European Society of Cardiology (ESC). Eur Heart J. 41:407–477.
2020. View Article : Google Scholar
|
|
17
|
Stoicescu M, Csepento C, Mutiu G and
Bungau S: The Role of increased plasmatic renin level in the
pathogenesis of arterial hypertension in young adults. Rom J
Morphol Embryol. 52 (Suppl 1):419–423. 2011.PubMed/NCBI
|
|
18
|
Eikelboom JW, Connolly SJ, Bosch J,
Dagenais GR, Hart RG, Shestakovska O, Diaz R, Alings M, Lonn EM,
Anand SS, et al: COMPASS Investigators: Rivaroxaban with or without
aspirin in stable cardiovascular disease. N Engl J Med.
377:1319–1330. 2017. View Article : Google Scholar
|
|
19
|
Brooks M: FDA Okays Rivaroxaban Plus
Aspirin for Chronic CAD, PAD. Medscape. 2018.https://www.medscape.com/viewarticle/903344.
Accessed October 12, 2018.
|
|
20
|
Raskob GE, van Es N, Verhamme P, Carrier
M, Di Nisio M, Garcia D, Grosso MA, Kakkar AK, Kovacs MJ, Mercuri
MF, et al: Hokusai VTE Cancer Investigators: Edoxaban for the
treatment of cancer-associated venous Thromboembolism. N Engl J
Med. 378:615–624. 2018.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Young AM, Marshall A, Thirlwall J, Chapman
O, Lokare A, Hill C, Hale D, Dunn JA, Lyman GH, Hutchinson C, et
al: Comparison of an oral factor Xa inhibitor with low molecular
weight heparin in patients with cancer with venous thromboembolism:
Results of a randomized trial (SELECT-D). J Clin Oncol.
36:2017–2023. 2018.PubMed/NCBI View Article : Google Scholar
|
|
22
|
McBane RD II, Wysokinski WE, Le-Rademacher
J, Zemla T, Ashrani A, Tafur A, Perepu U, Anderson D, Gundabolu K,
Kuzma C, et al: Apixaban and Dalteparin in Active
Malignancy-Associated Venous Thromboembolism: The ADAM VTE Trial. J
Thromb Haemost. 18:411–421. 2020.PubMed/NCBI View Article : Google Scholar
|
|
23
|
U.S. National Library of Medicine:
Apixaban for the Treatment of Venous Thromboembolism in Patients
With Cancer (CARAVAGGIO). uriClinicalTrials.govsimpleClinicalTrials.gov
Identifier: NCT03045406. https://www.clinicaltrials.gov/ct2/show/NCT03045406.
Accessed February 7, 2017.
|
|
24
|
Carrier M, Abou-Nassar K, Mallick R,
Tagalakis V, Shivakumar S, Schattner A, Kuruvilla P, Hill D,
Spadafora S, Marquis K, et al: AVERT Investigators: Apixaban to
prevent venous thromboembolism in patients with cancer. N Engl J
Med. 380:711–719. 2019.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Tica OA, Tica O, Antal L, Hatos A, Popescu
MI, Stoian AP, Bratu O, Gaman MA, Pituru SM and Diaconu C: Modern
oral anticoagulant treatment in patients with atrial fibrillation
and heart failure: Insights from the clinical practice. Farmacia.
66:972–976. 2018. View Article : Google Scholar
|
|
26
|
Oprita R, Ilie M, Sandru V, Berceanu D and
Constantinescu G: Gastrointestinal bleeding in patients admitted to
the intensive care unit. Arch Balk Med Union. 53:544–550.
2018.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Iliescu LE, Mercan-Stanciu A, Toma L and
Ioanitescu S: Antiphospholipid syndrome - a life-threatening
condition. Rev Rom Med Lab. 27:333–337. 2018. View Article : Google Scholar
|
|
28
|
Abdel-Daim MM, El-Tawil OS, Bungau SG and
Atanasov AG: Applications of antioxidants in metabolic disorders
and degenerative diseases: Mechanistic approach. Oxid Med Cell
Longev. 2019(4179676)2019.PubMed/NCBI View Article : Google Scholar
|
